Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

SOPHIA ANTIPOLIS, France, October 22 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today reported financial results for the nine months ended September 30, 2008.

Key highlights of the third quarter of 2008:

- Positive top-line results from the 302 study for naproxcinod. The study

met all three co-primary efficacy endpoints at week-13 (p<0.001) and

naproxcinod 750 mg bid comfortably met the main secondary endpoint of

non-inferiority to naproxen 500 mg bid at week-13 and 26. Blood

pressure data from the 302 study also supported naproxcinod's non-

detrimental effect on blood pressure.

- Good overall long term safety demonstrated for both doses of

naproxcinod in the 301 extension study, with no unexpected safety

findings. In addition, the patients' mean blood pressure remained

stable for the 52 weeks following the completion of the 301 study,

suggesting that naproxcinod does not increase blood pressure over time.

- Exclusive agreement signed with Capsugel, the leading

producer of two-piece capsules, for the commercial manufacture of

naproxcinod capsules. Capsugel will be responsible for the formulation

and encapsulation of naproxcinod API.

- Enrollment of 417 osteoarthritis patients with controlled

hypertension successfully completed in two Ambulatory Blood Pressure

Monitoring (ABPM) trials, the 111 and 112 studies. These trials are

designed to assess the 24-hour blood pressure profile of naproxcinod,

in comparison to ibuprofen and naproxen.

- PF-03187207 demonstrated an improvement over Xalatan(R) 0.005% in a

Japanese phase 2 study in glaucoma, although the primary endpoint

at day 28 was not met. NicOx is currently discussing the rights to

PF-03187207 with Pfizer to allow its potential continued development

and commercialization, following Pfi
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014 The Alliance ... a survey of European physicians at the "1 ... and Biological Therapies" at the Spanish Ministry of ... by EuropaBio and the Spanish Bioindustry Association (ASEBIO), ... physicians from Spanish oncology and rheumatology societies, representatives ...
(Date:11/26/2014)... Whitehouse Laboratories is pleased to announce ... (New Jersey) Chamber of Commerce as a member. ... in the North Jersey area, offers Whitehouse Laboratories ... clients in the pharmaceutical and biotechnology areas that ... enables Whitehouse Laboratories a higher level of visibility ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 The Pittcon ... its official conference and exposition mobile app, ... free download in the App Store for iOS and ... valuable resource tool before, during and after the event. ... details on exhibiting companies, technical sessions, Conferee Networking sessions ...
(Date:11/26/2014)... PLAINSBORO, N.J. and WILMINGTON, DE (PRWEB) November 26, 2014 ... the 2nd Annual MPN Heroes recognition reception on December ... Society of Hematology’s annual meeting. The MPN Heroes event ... significant contributions in the field of myeloproliferative neoplasms (MPNs). ... TV show "Nashville," will discuss his family's cancer journey ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... September 2 According to a new,market research ... MarketsandMarkets ( http://www.marketsandmarkets.com ), the global,biosimilars market is ... recording,a CAGR of 89.1% from 2009 to 2014. ... to reduce the costs of blockbuster,biopharmaceuticals has created ...
... , WALTHAM, Mass., Sept. 2 Repligen Corporation ... and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at ... 9th, 2009 at 2:25 p.m. EDT at the New York Palace ... webcast of the presentation will be available via Repligen,s website at ...
... of the problem: In a swarm of small fish it ... found in the microcosm of atoms and molecules, whose behavior ... control over single electrons in a bunch, ultrashort light pulses ... Max Planck Institute of Quantum Optics (MPQ) in Garching and ...
Cached Biology Technology:MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014 2MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014 3Repligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT 2Repligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT 3Laser pulses control single electrons in complex molecules 2Laser pulses control single electrons in complex molecules 3
(Date:11/4/2014)... at the right time might actually help boost a ... help in understanding animal populations, pest control and managing ... the journal Trends in Ecology and Evolution , ... the kind of positive population effect an overall species ... on the size and developmental stage of the creatures ...
(Date:11/4/2014)... about the way our bodies are assembled during early ... they are supposed to become a nerve or a ... correct place and alignment? Researchers at the University of ... a new study, UM researchers describe the signaling systems ... at the head-trunk region. Their discovery may have important ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... NEW YORK , Aug. 15, 2013   ... authentication solutions, announced today the appointment of Michael ...  Fiorito,s appointment reinforces the adoption and expansion of ... enterprise market. In this role, Fiorito ...
... German researchers have identified four biomarkers that correctly determine ... accurate prediction of patient outcomes. Their results are published ... Molecular Diagnostics . Current prognosticators of bladder cancer, ... foci, have limited usefulness for clinicians since they do ...
... who often recall their dreams respond more strongly to their ... mysteries of human cognition. It is still not fully known ... them. A major difficulty for studying dreams is that they ... Ruby and colleagues from the Lyon Neuroscience Research Center chose ...
Cached Biology News:EyeLock Appoints Michael Fiorito Vice President of Enterprise Accounts 2MicroRNAs have diagnostic and prognostic potential in urinary bladder cancer 2Frontiers news briefs: Aug. 13 2Frontiers news briefs: Aug. 13 3